Search

Objective To analyse the trend of COPD patients' inpatient costs and its influencing factors in the context of the reform of DRG, and to provide reference for the reasonable control of COPD inpatient costs. Methods ITSA were used to analyse the trend of COPD patients' inpatient costs in a tertiary general hospital from 2018 to 2022, and univariate analysis, stepwise regression analysis and RFM were used to analyse the factors influencing the inpatient costs and the degree of significance of COPD patients' inpatient costs after the official operation of the DRG. Results The results of ITSA showed that the overall inpatient costs of COPD patients decreased significantly and by an average of 1.82% per month during the DRG operation stage; the integrated medical service fee, drug fee, and consumable fee all showed a decreasing trend during the DRG operation stage, by an average of 1.06%, 1.67%, and 4. 98% per month, respectively, but the proportion of the integrated medical service fee increased compared with that before the DRG reform by 7.18%; The stepwise regression results showed that the number of hospital days (β = 0.584), admission status (β = 0.294), whether surgery (β = 0.125), whether traditional Chinese medicine (β = 0.084), and drug share ratio (β = 0.099) had a statistically significant impact on COPD hospitalisation costs (P < 0.05); and the results of the Random Forest model analysis showed that hospital days, admission status, drug share ratio were the most important factors influencing COPD hospitalisation costs, status, and medication ratio were the key factors affecting COPD hospitalisation costs. Conclusion DRG can effectively promote medical institutions to strengthen cost management and reduce the economic burden of disease. Hospitals should further reduce the cost of COPD and the economic burden of patients by reducing the number of inpatient days, strengthening the management of critically ill patients, and promoting the rational use of drugs. [ABSTRACT FROM AUTHOR]

Organic near‐infrared room temperature phosphorescence (RTP) materials offer remarkable advantages in bioimaging due to their characteristic time scales and background noise elimination. However, developing near‐infrared RTP materials for deep tissue imaging still faces challenges since the small band gap may increase the non‐radiative decay, resulting in weak emission and short phosphorescence lifetime. In this study, fused‐ring pyrrole‐based structures were employed as the guest molecules for the construction of long wavelength emissive RTP materials. Compared to the decrease of the singlet energy level, the triplet energy level showed a more effectively decrease with the increase of the conjugation of the substituent groups. Moreover, the sufficient conjugation of fused ring structures in the guest molecule suppresses the non‐radiative decay of triplet excitons. Therefore, a near‐infrared RTP material (764 nm) was achieved for deep penetration bioimaging. Tumor cell membrane is used to coat RTP nanoparticles (NPs) to avoid decreasing the RTP performance compared to traditional coating by amphiphilic surfactants. RTP NPs with tumor‐targeting properties show favorable phosphorescent properties, superior stability, and excellent biocompatibility. These NPs are applied for time‐resolved luminescence imaging to eliminate background interference with excellent tissue penetration. This study provides a practical solution to prepare long‐wavelength and long‐lifetime organic RTP materials and their applications in bioimaging. [ABSTRACT FROM AUTHOR]